Kizaki M, Ueno H, Yamazoe Y, Shimada M, Takayama N, Muto A, Matsushita H, Nakajima H, Morikawa M, Koeffler H P, Ikeda Y
Division of Hematology, Keio University School of Medicine, Tokyo, Japan.
Blood. 1996 Jan 15;87(2):725-33.
Retinoic acid (RA) regulates the differentiation and proliferation of a wide variety of different cell types and all-trans RA induces complete remission in a high proportion of patients with acute promyelocytic leukemia (APL). However, clinical resistance to retinoids may develop and poses a serious problem for differentiation-inducing therapy. We studied the effects of RA in combination with a cytochrome P450 inhibitor (clotrimazole) and a P-glycoprotein antagonist (verapamil) on cell growth and differentiation of RA-resistant HL-60 cells and fresh RA-resistant leukemic cells from two APL patients. RA-resistant HL-60 cells and APL cells differentiated to mature granulocytes when cultured with all-trans RA and either clotrimazole and verapamil but not with either of the agents alone. These findings were confirmed in these cells by their increased expression of CD11b antigen and migration-inhibitory factor-related protein-8/14 mRNAs and decreased levels of c-myc mRNA. These combinations also markedly decreased the number of viable cells and inhibited cellular proliferation. After isolation of microsomes, measurements showed that levels of cytochrome P450 activities in both wild-type and RA-resistant HL-60 cells were almost comparable. Moreover, expression of the CYP1A1-type cytochrome P450 gene could not be detected in either cell type. However, RA-resistant HL-60 cells and APL cells, but not RA-sensitive HL-60 cells and APL cells, expressed multidrug-resistance-1 gene transcripts. Taken together, acquired resistance to RA may be explained in part by drug metabolism in leukemic cells. Possible mechanisms for accelerated clearance of RA include the induction of non-CYP1A1 cytochrome P450 enzymes and P-glycoprotein.
维甲酸(RA)可调节多种不同细胞类型的分化和增殖,全反式维甲酸能使高比例的急性早幼粒细胞白血病(APL)患者实现完全缓解。然而,临床上可能会出现对维甲酸的耐药性,这给诱导分化治疗带来了严重问题。我们研究了RA与细胞色素P450抑制剂(克霉唑)和P-糖蛋白拮抗剂(维拉帕米)联合使用对RA耐药的HL-60细胞以及两名APL患者的新鲜RA耐药白血病细胞的细胞生长和分化的影响。当用全反式维甲酸与克霉唑或维拉帕米共同培养时,RA耐药的HL-60细胞和APL细胞可分化为成熟粒细胞,但单独使用其中任何一种药物时则不能。这些细胞中CD11b抗原、迁移抑制因子相关蛋白-8/14 mRNA表达增加以及c-myc mRNA水平降低,证实了这些发现。这些联合用药还显著减少了活细胞数量并抑制了细胞增殖。分离微粒体后测量显示,野生型和RA耐药的HL-60细胞中的细胞色素P450活性水平几乎相当。此外,在两种细胞类型中均未检测到CYP1A1型细胞色素P450基因的表达。然而,RA耐药的HL-60细胞和APL细胞表达多药耐药-1基因转录本,而RA敏感的HL-60细胞和APL细胞则不表达。综上所述,白血病细胞中的药物代谢可能部分解释了对RA产生的获得性耐药。RA清除加速的可能机制包括非CYP1A1细胞色素P450酶和P-糖蛋白的诱导。